Allergy Therapeutics Wins German Approval for Grass Pollen Allergy Drug

04:51 AM EST, 12/16/2025 (MT Newswires) -- Germany's Paul Ehrlich Institut granted marketing authorization for Allergy Therapeutics' (AGY.L) Grass Mata MPL, a subcutaneous immunotherapy for adults with moderate to severe grass pollen allergy. The company's application was based on data from the late-stage G306 trial in adults, in which the drug showed a highly statistically significant and clinically relevant reduction in allergy symptoms versus placebo during the peak pollen season, according to a Tuesday filing. Grass Mata MPL, which will be marketed as Grassmuno, is expected to begin commercialization in Germany by the first quarter of 2026. The biotechnology company also plans to continue exploring further registration opportunities in other major global markets.